OPK

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2002, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company is a biotechnology firm that shifted its strategy in 2002 from internal discovery research to acquiring external drug candidates in or near clinical development. During the period, the company terminated most internal scientific programs, including the Taxanes production program and the OASIS platform, retaining only limited operations for its Quantum Core Technology (QCT) platform.

Key Financial Metrics

Debt and Liquidity: The company has no material long-term debt other than capital lease obligations totaling $202,000 ($94,000 current). Management believes existing cash and investments are sufficient to fund operations through at least January 1, 2004.

Material Changes Versus Prior Period

• Revenue Decline: Revenue decreased by 58% to $562,000, primarily due to the completion of the research and development funding agreement with Bristol-Myers Squibb (BMS). A new $20,000 laboratory services agreement provided minimal offset.
• Increased Net Loss: Net loss increased by 17.9% to $10.36 million. This was driven by significant one-time charges despite reductions in operating expenses.
• Merger Expenses: The company incurred $2,010,000 in expenses related to a terminated merger agreement with Innovative Drug Delivery Systems (IDDS), including a $500,000 termination fee and a $500,000 reserve for a convertible note received from IDDS.
• Strategic Redirection Costs: Expenses of $864,000 were recognized for strategic redirection, including severance payments ($298,000), facility lease commitments for terminated operations ($186,000), and equipment write-downs ($161,000).
• Operating Expense Reductions: Research and Development expenses decreased 18% to $3.95 million, and General and Administrative expenses decreased 26% to $4.77 million, reflecting the termination of non-productive programs and personnel reductions.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects to require additional financing in the future to fund operations beyond early 2004. The company is actively evaluating other companies and technologies for acquisition to accelerate clinical development.
• Stock Listing Risk: The company's common stock was transferred to the Nasdaq SmallCap Market in October 2002 due to failure to meet the $1.00 minimum bid price requirement. The company received a 180-day extension until July 21, 2003, to regain compliance. Failure to meet this requirement could result in delisting.
• Legal Proceedings:
  • MSI/Accelrys: The company is negotiating to terminate participation agreements with Accelrys (successor to MSI) due to unmet milestones, with $127,000 accrued in expenses.
  • EEOC Charge: A former employee filed a charge of discrimination with the EEOC; the company intends to defend vigorously.
• Unusual Items: The $2.01 million merger expense and $864,000 strategic redirection charge are non-recurring items significantly impacting the 2002 bottom line.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $16.2 million cash position to sustain operations through 2004 given the lack of recurring revenue.
• Acquisition Strategy: Assess the progress of the new strategy to acquire external drug candidates, as internal R&D has been largely discontinued.
• Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement by July 21, 2003, to avoid delisting.
• Merger Note Valuation: Review the $500,000 convertible note received from IDDS, which was fully reserved against due to valuation uncertainties.
• Legal Contingencies: Track the resolution of the Accelrys contract dispute and the EEOC discrimination charge.